Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
31.14 EUR | +0.71% | +7.53% | -24.20% |
Apr. 23 | Pharma Mar, S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Feb. 29 | Transcript : Pharma Mar, S.A., 2023 Earnings Call, Feb 29, 2024 |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Its low valuation, with P/E ratio at 12.11 and 6.29 for the ongoing fiscal year and 2026 respectively, makes the stock pretty attractive with regard to earnings multiples.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-24.20% | 592M | B+ | ||
+1.45% | 40.51B | A- | ||
-15.94% | 31.67B | B- | ||
+52.66% | 24.62B | A | ||
-14.50% | 15.65B | C | ||
-14.38% | 12.07B | B- | ||
-9.12% | 11.97B | D+ | ||
-42.56% | 11.61B | B | ||
+4.87% | 8.81B | B+ | ||
-4.33% | 8.5B | B- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- PHM Stock
- Ratings Pharma Mar, S.A.